item 2 . properties . we conduct our primary operations at the owned and leased facilities described below . location operations conducted approximate square feet expiration new haven , connecticut corporate headquarters and executive , sales , research and development offices 514000 .

operations conducted: new haven connecticut: corporate headquarters and executive sales research and development offices
dublin ireland: global supply chain distribution and administration offices
lexington massachusetts: research and development offices
bogart georgia: commercial research and development manufacturing
smithfield rhode island: commercial research and development manufacturing
zurich switzerland: regional executive and sales offices
approximatesquare feet: new haven connecticut: 514000
dublin ireland: 215000
lexington massachusetts: 81000
bogart georgia: 70000
smithfield rhode island: 67000
zurich switzerland: 69000
leaseexpirationdates: new haven connecticut: 2030
dublin ireland: owned
lexington massachusetts: 2019
bogart georgia: 2024
smithfield rhode island: owned
zurich switzerland: 2025

we believe that our administrative office space is adequate to meet our needs for the foreseeable future . we also believe that our research and development facilities and our manufacturing facility , together with third party manufacturing facilities , will be adequate for our on-going activities . in addition to the locations above , we also lease space in other u.s . locations and in foreign countries to support our operations as a global organization . as of december 31 , 2015 , we also leased approximately 254000 square feet in cheshire , connecticut , which was the previous location of our corporate headquarters and executive , sales , research and development offices . in december 2015 , we entered into an early termination of this lease and will occupy this space through may 2016 . in april 2014 , we purchased a fill/finish facility in athlone , ireland . following refurbishment of the facility , and after successful completion of the appropriate validation processes and regulatory approvals , the facility will become our first company-owned fill/finish and packaging facility for our commercial and clinical products . in may 2015 , we announced plans to construct a new biologics manufacturing facility on our existing property in dublin ireland , which is expected to be completed by 2020 . item 3 . legal proceedings . in may 2015 , we received a subpoena in connection with an investigation by the enforcement division of the sec requesting information related to our grant-making activities and compliance with the fcpa in various countries . the sec also seeks information related to alexion 2019s recalls of specific lots of soliris and related securities disclosures . in addition , in october 2015 , alexion received a request from the doj for the voluntary production of documents and other information pertaining to alexion's compliance with the fcpa . alexion is cooperating with these investigations . at this time , alexion is unable to predict the duration , scope or outcome of these investigations . given the ongoing nature of these investigations , management does not currently believe a loss related to these matters is probable or that the potential magnitude of such loss or range of loss , if any , can be reasonably estimated . item 4 . mine safety disclosures . not applicable. .

Questions:
what is the sum of square footage for the new haven and lexington properties?
what is the square footage in bogart?
what is the total sum of those 3 locations?
what is the square footage of zurich?
what is the total sum?

Answers:
595000
70000
665000
69000
734000